Publications by authors named "Joyce Plested"

Claim this Profile
D
Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine.
Mingzhu Zhu, Edmond Massuda, Urvashi Patel, Gordon Chau, Raj Kalkeri, Joyce S Plested

J Med Virol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).
Germán Áñez, Alice McGarry, Wayne Woo, Karen L Kotloff, Cynthia L Gay, Joyce S Plested

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprinting.
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Anand Parekh, Drew Gorinson, Joyce S Plested

J Infect· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses.
Jeffrey M Adelglass, Paul Bradley, Miranda R Cai, Gordon Chau, Raj Kalkeri, Joyce S Plested

J Allergy Clin Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Katia Alves, Karen Kotloff, R Scott McClelland, Alex Kouassi, Joyce S Plested

Lancet Infect Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
Katia Alves, Alex Kouassi, Joyce S Plested, Raj Kalkeri, Katherine Smith

Vaccine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.
Chijioke Bennett, Gordon Chau, Erika Clayton, Laurence Chu, Jacqueline Alvarez, Joyce S Plested

J Infect· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines.
Anthony M Marchese, Louis Fries, Hadi Beyhaghi, Muruga Vadivale, Mingzhu Zhu, Joyce S Plested

J Infect· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Joyce S Plested

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harmonization of Vaccine Ligand Binding Assays Validation.
Francis Dessy, Ivo Sonderegger, Leslie Wagner, Alessandra Buoninfante, Meenu Wadhwa, Joyce Plested

Bioanalysis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine.
Timothy S Vincent, Mingzhu Zhu, Anand Parekh, Urvashi Patel, Shane Cloney-Clark, Joyce S Plested

Microorganisms· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
Chijioke Bennett, E Joy Rivers, Wayne Woo, Mark Bloch, King Cheung, Joyce S Plested

J Infect Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Chijioke Bennett, Wayne Woo, Mark Bloch, King Cheung, Paul Griffin, Joyce S Plested

Lancet Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity.
Stephanie Hamilton, Mingzhu Zhu, Shane Cloney-Clark, Penny Mayes, Jen Fenner, Joyce S Plested

J Virol Methods· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity.
Zhaohui Cai, Raj Kalkeri, Mi Wang, Benjamin Haner, Dominic Dent, Joyce S Plested

Microorganisms· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines.
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Joyce S Plested, Anand Parekh

J Infect· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Zhaohui Cai, Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Benjamin Haner, Joyce S Plested

Microorganisms· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines.
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Joyce S Plested, Anand Parekh

medRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Prasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Joyce S Plested

Sci Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Louis Fries, Neil Formica, Raburn M Mallory, Haixia Zhou, Joyce S Plested

J Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R Cai, Gordon Chau, Joyce Plested

Vaccine· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection.
Mingzhu Zhu, Shane Cloney-Clark, Sheau-Line Feng, Anand Parekh, Drew Gorinson, Joyce S Plested

Microorganisms· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Bhagwat Gunale, Dhananjay Kapse, Sonali Kar, Ashish Bavdekar, Sunil Kohli, Joyce S Plested

JAMA Pediatr· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark

Vaccine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico.
Germán Áñez, Karen L Kotloff, Cynthia L Gay, Joy Nelson, Haoua Dunbar, Joyce S Plested

medRxiv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis